Who Paid My Doc
Liqrev
Drug Pulminary Arterial Hypertension - PAH
NDC 46287-055-01
General payments
$6,153
Research payments
$0
Through program year 2025, $6,153 in general payments and $0 in research payments were reported against Liqrev (Pulminary Arterial Hypertension - PAH).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $2,110 | 92 |
| 2024 | General | $2,087 | 93 |
| 2023 | General | $1,957 | 89 |
Breakdown
The top 5 of 40 recipients; each share is of general payments naming this product in 2025.
The top 5 of 19 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
274 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.